Selank has exactly one randomized human trial behind its safety reputation, and that trial wasn’t built to measure safety head-on. It compared an anxiolytic peptide to a decades-old benzodiazepine relative, in 62 people, for a few weeks, with nobody watching for what happens at month six.[1] Everything else repeated about Selank’s side effects, that it is gentle, that it skips the grogginess and dependence problems of standard anxiety drugs, traces back to a small cluster of Russian trials run by the same handful of research groups, plus animal work that raises as many questions as it answers. The peptide might genuinely have a favorable side-effect profile. Nobody has built the evidence to know that yet.
The one trial Selank’s reputation is built on
In 2008, Zozulia and colleagues ran the only Selank trial that looks anything like modern anxiety-drug research.[1] Thirty patients with generalized anxiety disorder or neurasthenia received Selank; 32 received medazepam, an older anxiolytic related to the benzodiazepines.
No placebo arm. The comparison is Selank versus another drug. It shows how the two performed against each other, and it says nothing about what either one does compared with taking no drug at all.
Similar anxiolytic effect, plus extras. The two drugs worked about equally well on anxiety symptoms, but Selank additionally produced antiasthenic and psychostimulant effects that medazepam did not.[1]
62 patients cannot catch a rare problem. A side effect that shows up in 1 in 200 people would need a trial many times this size to appear at all, let alone reliably.
62 patients in the only randomized Selank trial PMID 18454096
Because patients were randomly assigned to one drug or the other, the design supports a genuine causal comparison between the two. That part holds up. What it cannot do is speak to long-term use: the trial ran for weeks, and once patients went home, nobody in this record kept watching.
What the human data says about side effects specifically
The most direct side-effect claim in the literature comes not from the 2008 trial but from the biochemical end of the same research program. Zozulya and colleagues reported that Selank dose-dependently blocked the enzymes that break down plasma enkephalin, at a concentration around 15 micromolar, more potently than the reference peptidase inhibitors bacitracin and puromycin, and used that mechanism to argue the peptide could calm anxiety without producing the side effects typical of most anxiolytics.[2]
That is a claim from the compound’s own developers, built on an in-vitro assay and a small clinical observation, not an independent tolerability study designed to catch what patients report unprompted.
A more useful data point on side effects comes from a different angle: what happens when Selank is added to a drug with an already well-known side-effect profile. Medvedev and colleagues gave phenazepam alone to 30 patients and phenazepam plus Selank to 40 patients with anxiety-phobic, hypochondriac, or somatoform disorders, and found the combination group had fewer of phenazepam’s own side effects: less attention and memory impairment, less asthenia, less sedation, less lengthening of sleep duration, fewer sexual disturbances, less emotional flatness, and less orthostatic dizziness, both during treatment and after the benzodiazepine was withdrawn.[3]
The pattern that holds up across two separate trials from two different groups: Selank shows up as the drug that reduces someone else’s side effects rather than adding its own. Whether that holds at the doses and durations people use outside these studies is untested.
Mechanisms that could plausibly cause problems nobody has looked for
Selank’s enkephalinase-inhibiting mechanism ties it to the opioid-adjacent signaling system, the same broad category implicated in side effects for other drugs that block peptide-degrading enzymes.[2] Compare it to ACE inhibitors: blocking one enzyme to lower blood pressure also blocks that enzyme’s other substrates, which is why a persistent dry cough shows up as an on-target side effect in a meaningful share of patients. Nobody has published the equivalent off-target screening for Selank.
There is a second mechanism worth flagging. A 2006 comparison study tested the anticoagulant specificity of Semax and Selank alongside a related family of peptides called glyprolines, tying both compounds to a hemostasis-relevant pathway.[4] The record available doesn’t give the magnitude of Selank’s effect or say whether it matters at the doses used in the anxiety trials.
What no one has measured: whether Selank’s own anticoagulant activity is large enough at study doses to matter for someone on blood thinners, or scheduled for surgery.
Selank’s reach isn’t limited to the nervous system either. A 2014 study in mice found that Selank and its short fragment Gly-Pro altered the expression of several immune-related genes in the spleen within 30 to 90 minutes of injection, including a rapid drop in complement C3 mRNA.[5] That’s a single-injection, single-species finding, not evidence of a clinically meaningful immune effect in a person using nasal Selank for weeks. It is one more system where the systemic pharmacology hasn’t been characterized in humans, and no published side-effect study has looked at it.
Then there is the animal data on individual variability. In BALB/c and C57BL/6 mice, the same 0.3 mg/kg dose of Selank raised norepinephrine in the hypothalamus of both strains, but pushed dopamine metabolites in opposite directions between the two strains, and lowered serotonin only in the BALB/c animals.[6] Two genetically distinct mouse lines had two different neurochemical responses to an identical dose. Human genetic variation dwarfs the difference between two inbred mouse strains, in roughly the way CYP450 variants make some people fast metabolizers of SSRIs and others slow ones. If Selank’s neurochemical footprint is this strain-dependent in mice, one tidy side-effect profile applied to every human user is optimistic.
The intranasal route helps, in theory
Selank is delivered nasally rather than injected or swallowed, and there’s a real pharmacological reason to expect that matters. A review of intranasal peptide and protein delivery notes that the route minimizes exposure to peripheral organs and tissues, which should reduce systemic side effects compared with other delivery methods, while giving a fragile peptide time to act before it degrades in the blood.[7] That review isn’t about Selank; it covers albumin, insulin, and several other peptides delivered the same way. The logic is general pharmacology, applied to Selank by inference rather than tested on it directly.
That inference is a legitimate reason for cautious optimism about Selank’s systemic exposure. It is not evidence that the reasoning holds for this particular molecule at the doses sold commercially.
What nobody has tested
Pregnancy and children. No published study covers either population.
Combination with SSRIs or other psychiatric drugs, beyond the one phenazepam trial above. No published study looks at SSRI combinations specifically.
Independent replication outside Russia. The trials that exist come from the same cluster of research institutions that developed the compound. No outside group has run the comparison.
What retail products contain. No independent laboratory analysis of Selank purchased outside a clinical trial setting appears in this record, which means the trial safety data applies to material nobody outside those trials has verified matches what is sold at retail.
Bottom line: the honest version of Selank’s side-effect profile reads “mild in a handful of short trials from one research cluster, doing things nobody has replicated independently, at doses and durations nobody has confirmed match what’s sold commercially.”
Where Selank sits next to its usual comparisons
Semax vs Selank: two Russian peptides, one shared evidence problem covers the sister peptide most often mentioned in the same breath, and the comparison matters here too. Semax shares the same thin, single-institution evidence base. Pointing to Semax as reassurance about Selank just cites one unproven peptide to vouch for another.
Benzodiazepines are the more honest comparison. Not because they’re safer in absolute terms (several carry real dependence and withdrawal risk), but because decades of prescriptions and pharmacovigilance mean their side-effect profile is documented with a precision Selank’s simply isn’t. A drug can be well understood and risky, or poorly understood and mild. Selank is the second kind. The retail market sells it like the first.
GHK-Cu Peptide Injection: The Human Evidence Gap tells the same story with a different peptide: strong marketing, thin independent human data. Selank’s evidence base is arguably narrower still, since GHK-Cu at least has topical human trials for skin outcomes with no real Selank equivalent.
For the anxiolytic claims themselves, rather than the side effects, Selank for Anxiety: What the Research Protocols Show covers what the 2008 and 2015 trials tested.
Anyone taking Selank today is relying on two small trials, a handful of strain-dependent animal studies, and a mechanism paper from the compound’s own developers. Call that a reasonable starting point for a curious researcher. Do not call it a safety profile.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.. Bulletin of experimental biology and medicine, 2001.
[Optimization of the treatment of anxiety disorders with selank].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015.
[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].. Izvestiia Akademii nauk. Seriia biologicheskaia, 2006.
The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.. Molecular immunology, 2014.
[Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study].. Eksperimental'naia i klinicheskaia farmakologiia, 2008.
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases.. The AAPS journal, 2015.
